{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T13:33:54Z","timestamp":1776692034067,"version":"3.51.2"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ctrv.2020.102106","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T22:24:01Z","timestamp":1600727041000},"page":"102106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Liquid biopsy in lymphoma: Molecular methods and clinical applications"],"prefix":"10.1016","volume":"91","author":[{"given":"Melita","family":"Cirillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1720-8687","authenticated-orcid":false,"given":"Alexander F.M.","family":"Craig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sven","family":"Borchmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Kurtz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ctrv.2020.102106_b0005","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/s41375-018-0043-y","article-title":"Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma","volume":"32","author":"Araf","year":"2018","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.ctrv.2020.102106_b0010","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V128.22.1752.1752","article-title":"Noninvasive detection of ibrutinib resistance in non-hodgkin lymphoma using cell-free DNA","volume":"128","author":"Scherer","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ctrv.2020.102106_b0015","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"New England J Med"},{"issue":"31","key":"10.1016\/j.ctrv.2020.102106_b0020","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2016.67.1305","article-title":"Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group","volume":"34","author":"Kovacs","year":"2016","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.ctrv.2020.102106_b0025","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1182\/blood-2016-05-714162","article-title":"Minimal residual disease is an independent predictor for 10-year survival in CLL","volume":"128","author":"Kwok","year":"2016","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.ctrv.2020.102106_b0030","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102106_b0035","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2020.102106_b0040","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"issue":"364","key":"10.1016\/j.ctrv.2020.102106_b0045","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"issue":"14","key":"10.1016\/j.ctrv.2020.102106_b0050","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse large B-cell lymphoma genotyping on the liquid biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102106_b0055","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood-2018-99-112573","article-title":"Circulating Tumor DNA Dynamics during Therapy Predict Outcomes in Mantle Cell Lymphoma","volume":"132","author":"Lakhotia","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102106_b0060","unstructured":"Melani C, Pittaluga S, Yee L, Lucas A, Shovlin M, Jacob A, et al. Next-Generation Sequencing Based Monitoring of Circulating-Tumor DNA in Untreated Peripheral T-Cell Lymphoma. Blood. 2017;130(Suppl 1):2728."},{"issue":"15_suppl","key":"10.1016\/j.ctrv.2020.102106_b0065","doi-asserted-by":"crossref","first-page":"7576","DOI":"10.1200\/JCO.2018.36.15_suppl.7576","article-title":"Circulating tumor DNA to predict timing of relapse in mantle cell lymphoma","volume":"36","author":"Roschewski","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2020.102106_b0070","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/hon.2_2630","article-title":"Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study","volume":"37","author":"Camus","year":"2019","journal-title":"Hematol Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2020.102106_b0075","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1365-2141.2012.09209.x","article-title":"Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase","volume":"158","author":"Muringampurath-John","year":"2012","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.ctrv.2020.102106_b0080","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/annonc\/mdp006","article-title":"Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas","volume":"20","author":"Hohaus","year":"2009","journal-title":"Ann Oncol: Off J Europ Soc Med Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2020.102106_b0085","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"issue":"28","key":"10.1016\/j.ctrv.2020.102106_b0090","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2020.102106_b0095","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1038\/leu.2014.137","article-title":"High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial","volume":"28","author":"Rossille","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.ctrv.2020.102106_b0100","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nbt.3520","article-title":"Integrated digital error suppression for improved detection of circulating tumor DNA","volume":"34","author":"Newman","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"12","key":"10.1016\/j.ctrv.2020.102106_b0105","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.ctrv.2020.102106_b0110","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/s41591-019-0652-7","article-title":"High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants","volume":"25","author":"Razavi","year":"2019","journal-title":"Nat Med"},{"issue":"23","key":"10.1016\/j.ctrv.2020.102106_b0115","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1182\/blood.V126.23.114.114","article-title":"Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma","volume":"126","author":"Scherer","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2020.102106_b0120","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution and residual disease in classical Hodgkin lymphoma","author":"Spina","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2020.102106_b0125","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41375-019-0541-6","article-title":"Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma","volume":"34","author":"Desch","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.ctrv.2020.102106_b0130","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"issue":"6769","key":"10.1016\/j.ctrv.2020.102106_b0135","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ctrv.2020.102106_b0140","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ctrv.2020.102106_b0145","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"Scott","year":"2014","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.ctrv.2020.102106_b0150","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"New England J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2020.102106_b0155","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"Supplement_1","key":"10.1016\/j.ctrv.2020.102106_b0160","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1182\/blood-2019-132069","article-title":"Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling","volume":"134","author":"Esfahani","year":"2019","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.ctrv.2020.102106_b0165","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2017-11-814913","article-title":"Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma","volume":"131","author":"Tiacci","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ctrv.2020.102106_b0170","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.ctrv.2020.102106_b0175","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1158\/1078-0432.CCR-14-2116","article-title":"Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas","volume":"21","author":"Braggio","year":"2015","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2020.102106_b0180","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/leu.2014.264","article-title":"The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing","volume":"29","author":"Vater","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2020.102106_b0185","doi-asserted-by":"crossref","unstructured":"Hiemcke-Jiwa LS, Leguit RJ, Snijders TJ, Bromberg JEC, Nierkens S, Jiwa NM, et al. MYD88 p.(L265P) detection on cell-free DNA in liquid biopsies of patients with primary central nervous system lymphoma. Brit J Haematol 2019;185(5):974\u20137.","DOI":"10.1111\/bjh.15674"},{"issue":"10","key":"10.1016\/j.ctrv.2020.102106_b0190","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/jamaophthalmol.2018.2887","article-title":"Potential Diagnosis of Vitreoretinal Lymphoma by Detection of MYD88 Mutation in Aqueous Humor With Ultrasensitive Droplet Digital Polymerase Chain Reaction","volume":"136","author":"Hiemcke-Jiwa","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.ctrv.2020.102106_b0195","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12885-019-5394-x","article-title":"Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas","volume":"19","author":"Hickmann","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2020.102106_b0200","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3389\/fonc.2018.00382","article-title":"Detection of the MYD88 p. L265P Mutation in the CSF of a Patient With Secondary Central Nervous System Lymphoma","volume":"8","author":"Zorofchian","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2020.102106_b0205","doi-asserted-by":"crossref","unstructured":"International Non-Hodgkin's Lymphoma Prognostic Factors P. A predictive model for aggressive non-Hodgkin's lymphoma. The New England J Med 1993;329(14):987\u201394.","DOI":"10.1056\/NEJM199309303291402"},{"issue":"11","key":"10.1016\/j.ctrv.2020.102106_b0210","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s00259-014-2822-7","article-title":"Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma","volume":"41","author":"Sasanelli","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Supplement_1","key":"10.1016\/j.ctrv.2020.102106_b0215","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2019-131081","article-title":"Assessment of Cell-Free DNA (cfDNA) in 221 Patients with Lymphoproliferative Malignancies at Diagnosis and during Follow-up","volume":"134","author":"Andrade-Campos","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ctrv.2020.102106_b0220","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-018-0111-6","article-title":"Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort","volume":"8","author":"Bohers","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ctrv.2020.102106_b0225","unstructured":"Schroers-Martin JG, Kurtz DM, Soo J, Jin M, Scherer F, Craig A, et al. Determinants of Circulating Tumor DNA Levels across Lymphoma Histologic Subtypes. Blood. 2017;130(Supplement 1):4018."},{"issue":"15","key":"10.1016\/j.ctrv.2020.102106_b0230","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"New England J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2020.102106_b0235","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/asheducation.V2012.1.397.3798512","article-title":"Interim PET-CT in the management of diffuse large B-cell lymphoma","volume":"2012","author":"Moskowitz","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"10.1016\/j.ctrv.2020.102106_b0240","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2019.06.011","article-title":"Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction","volume":"178","author":"Kurtz","year":"2019","journal-title":"Cell"},{"issue":"22","key":"10.1016\/j.ctrv.2020.102106_b0245","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"issue":"31","key":"10.1016\/j.ctrv.2020.102106_b0250","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.2014.55.7561","article-title":"Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma","volume":"32","author":"Thompson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2020.102106_b0255","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1200\/JCO.2009.26.5942","article-title":"Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma","volume":"28","author":"Moskowitz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2020.102106_b0260","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/MOH.0000000000000516","article-title":"The future of cell-free DNA testing to guide therapeutic decisions in B-cell lymphomas","volume":"26","author":"Condoluci","year":"2019","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"10.1016\/j.ctrv.2020.102106_b0265","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11899-019-0493-y","article-title":"The Emerging Role of Liquid Biopsies in Lymphoproliferative Disorders","volume":"14","author":"Crombie","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2020.102106_b0270","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/hon.2587","article-title":"Liquid biopsy in non-Hodgkin's lymphoma","volume":"37","author":"Melani","year":"2019","journal-title":"Hematol Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2020.102106_b0275","first-page":"509","article-title":"Measurement of circulating tumor DNA to guide management of patients with lymphoma","volume":"17","author":"Sriram","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2020.102106_b0280","first-page":"157","article-title":"Characterization of the cell-free DNA released by cultured cancer cells","volume":"1863","author":"Bronkhorst","year":"2016","journal-title":"BBA"},{"issue":"466","key":"10.1016\/j.ctrv.2020.102106_b0285","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat4921","article-title":"Enhanced detection of circulating tumor DNA by fragment size analysis","volume":"10","author":"Mouliere","year":"2018","journal-title":"Sci Transl Med"},{"issue":"7761","key":"10.1016\/j.ctrv.2020.102106_b0290","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","article-title":"Genome-wide cell-free DNA fragmentation in patients with cancer","volume":"570","author":"Cristiano","year":"2019","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ctrv.2020.102106_b0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023418","article-title":"High fragmentation characterizes tumour-derived circulating DNA","volume":"6","author":"Mouliere","year":"2011","journal-title":"PLoS ONE"},{"issue":"23","key":"10.1016\/j.ctrv.2020.102106_b0300","doi-asserted-by":"crossref","first-page":"8583","DOI":"10.1073\/pnas.1406103111","article-title":"Size-based molecular diagnostics using plasma DNA for noninvasive prenatal testing","volume":"111","author":"Yu","year":"2014","journal-title":"PNAS"},{"issue":"1","key":"10.1016\/j.ctrv.2020.102106_b0305","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1373\/clinchem.2003.024893","article-title":"Size distributions of maternal and fetal DNA in maternal plasma","volume":"50","author":"Chan","year":"2004","journal-title":"Clin Chem"},{"issue":"1\u20132","key":"10.1016\/j.ctrv.2020.102106_b0310","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cell.2015.11.050","article-title":"Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin","volume":"164","author":"Snyder","year":"2016","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ctrv.2020.102106_b0315","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1038\/s41467-019-12714-4","article-title":"Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection","volume":"10","author":"Ulz","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2020.102106_b0320","doi-asserted-by":"crossref","unstructured":"Mehrmohamadi M, Esfahani MS, Soo J, Scherer F, Schroers-Martin JG, Chen B, et al. Distinct Chromatin Accessibility Profiles of Lymphoma Subtypes Revealed By Targeted Cell Free DNA Profiling. Blood 2018;132(Supplement 1):672.","DOI":"10.1182\/blood-2018-99-119361"},{"key":"10.1016\/j.ctrv.2020.102106_b0325","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12920-015-0107-z","article-title":"High-resolution characterization of sequence signatures due to non-random cleavage of cell-free DNA","volume":"8","author":"Chandrananda","year":"2015","journal-title":"BMC Med Genomics"},{"issue":"4","key":"10.1016\/j.ctrv.2020.102106_b0330","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ccell.2019.09.003","article-title":"Toward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNA","volume":"36","author":"van der Pol","year":"2019","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.ctrv.2020.102106_b0335","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1002\/ijc.28593","article-title":"Commonality and differences of methylation signatures in the plasma of patients with pancreatic cancer and colorectal cancer","volume":"134","author":"Melson","year":"2014","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2020.102106_b0340","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1158\/0008-5472.CAN-13-3392","article-title":"Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer","volume":"74","author":"Fackler","year":"2014","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.ctrv.2020.102106_b0345","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/cr.2015.126","article-title":"Genome-scale detection of hypermethylated CpG islands in circulating cell-free DNA of hepatocellular carcinoma patients","volume":"25","author":"Wen","year":"2015","journal-title":"Cell Res"},{"issue":"9","key":"10.1016\/j.ctrv.2020.102106_b0350","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/ijc.30625","article-title":"Methylated free-circulating HPP1 DNA is an early response marker in patients with metastatic colorectal cancer","volume":"140","author":"Herbst","year":"2017","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2020.102106_b0355","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13073-017-0499-9","article-title":"Methylation patterns in serum DNA for early identification of disseminated breast cancer","volume":"9","author":"Widschwendter","year":"2017","journal-title":"Genome Med"},{"issue":"14","key":"10.1016\/j.ctrv.2020.102106_b0360","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1158\/1078-0432.CCR-18-0101","article-title":"Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients","volume":"24","author":"Gordevicius","year":"2018","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"7","key":"10.1016\/j.ctrv.2020.102106_b0365","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/ajh.24751","article-title":"Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma","volume":"92","author":"Wedge","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.ctrv.2020.102106_b0370","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13148-016-0261-y","article-title":"Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma","volume":"8","author":"Kristensen","year":"2016","journal-title":"Clin Epigenet"},{"key":"10.1016\/j.ctrv.2020.102106_b0375","article-title":"Epigenetic Changes in Cancer: The study of how covalent marks on DNA and histones are involved in the origin and spread of cancer cells is also leading to new therapeutic strategies","author":"Estreller","year":"2011","journal-title":"F1000 Biol Reports"},{"issue":"1","key":"10.1016\/j.ctrv.2020.102106_b0380","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/s41467-018-03961-y","article-title":"Non-invasive detection of human cardiomyocyte death using methylation patterns of circulating DNA","volume":"9","author":"Zemmour","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2020.102106_b0385","doi-asserted-by":"crossref","unstructured":"Hesson LP, A., editor. Clinical Epigenetics. Singapore: Springer Nature Singapore Ltd.; 2019.","DOI":"10.1007\/978-981-13-8958-0"},{"issue":"13","key":"10.1016\/j.ctrv.2020.102106_b0390","doi-asserted-by":"crossref","first-page":"E1826","DOI":"10.1073\/pnas.1519286113","article-title":"Identification of tissue-specific cell death using methylation patterns of circulating DNA","volume":"113","author":"Lehmann-Werman","year":"2016","journal-title":"PNAS"},{"issue":"40","key":"10.1016\/j.ctrv.2020.102106_b0395","doi-asserted-by":"crossref","first-page":"E5503","DOI":"10.1073\/pnas.1508736112","article-title":"Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments","volume":"112","author":"Sun","year":"2015","journal-title":"PNAS"},{"issue":"1","key":"10.1016\/j.ctrv.2020.102106_b0400","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1038\/s41467-018-07466-6","article-title":"Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease","volume":"9","author":"Moss","year":"2018","journal-title":"Nat Commun"},{"issue":"47","key":"10.1016\/j.ctrv.2020.102106_b0405","doi-asserted-by":"crossref","first-page":"18761","DOI":"10.1073\/pnas.1313995110","article-title":"Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing","volume":"110","author":"Chan","year":"2013","journal-title":"PNAS"},{"issue":"15","key":"10.1016\/j.ctrv.2020.102106_b0410","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gky423","article-title":"CancerDetector: ultrasensitive and non-invasive cancer detection at the resolution of individual reads using cell-free DNA methylation sequencing data","volume":"46","author":"Li","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.ctrv.2020.102106_b0415","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13059-017-1191-5","article-title":"CancerLocator: non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA","volume":"18","author":"Kang","year":"2017","journal-title":"Genome Biol"},{"issue":"10","key":"10.1016\/j.ctrv.2020.102106_b0420","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/cr.2017.106","article-title":"5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages","volume":"27","author":"Song","year":"2017","journal-title":"Cell Res"},{"issue":"52","key":"10.1016\/j.ctrv.2020.102106_b0425","doi-asserted-by":"crossref","first-page":"21083","DOI":"10.1073\/pnas.1320659110","article-title":"Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients","volume":"110","author":"Ni","year":"2013","journal-title":"PNAS"},{"issue":"5","key":"10.1016\/j.ctrv.2020.102106_b0430","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nbt.2892","article-title":"Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer","volume":"32","author":"Lohr","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"8","key":"10.1016\/j.ctrv.2020.102106_b0435","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1186\/s13059-014-0452-9","article-title":"Cancer genomics: one cell at a time","volume":"15","author":"Navin","year":"2014","journal-title":"Genome Biol"},{"issue":"3","key":"10.1016\/j.ctrv.2020.102106_b0440","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrg.2015.16","article-title":"Single-cell genome sequencing: current state of the science","volume":"17","author":"Gawad","year":"2016","journal-title":"Nat Rev Genet"},{"issue":"5","key":"10.1016\/j.ctrv.2020.102106_b0445","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","article-title":"Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis","volume":"20","author":"Labelle","year":"2011","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.ctrv.2020.102106_b0450","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ccell.2015.09.018","article-title":"RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics","volume":"28","author":"Best","year":"2015","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.ctrv.2020.102106_b0455","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1752-8062.2010.00226.x","article-title":"Significant downregulation of platelet gene expression in metastatic lung cancer","volume":"3","author":"Calverley","year":"2010","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.ctrv.2020.102106_b0460","doi-asserted-by":"crossref","unstructured":"Best MG, Sol N, In 't Veld S, Vancura A, Muller M, Niemeijer AN, et al. Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets. Cancer Cell 2017;32(2):238\u201352.e9.","DOI":"10.1016\/j.ccell.2017.07.004"},{"issue":"7","key":"10.1016\/j.ctrv.2020.102106_b0465","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/cbf.1690","article-title":"The virtosome-a novel cytosolic informative entity and intercellular messenger","volume":"28","author":"Gahan","year":"2010","journal-title":"Cell Biochem Funct"},{"issue":"10","key":"10.1016\/j.ctrv.2020.102106_b0470","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/annonc\/mdy261","article-title":"Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma","volume":"29","author":"Krug","year":"2018","journal-title":"Ann Oncol: Off J Europ Soc Med Oncol"},{"issue":"19","key":"10.1016\/j.ctrv.2020.102106_b0475","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89631","article-title":"Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients","volume":"1","author":"van Eijndhoven","year":"2016","journal-title":"JCI Insight"},{"issue":"14","key":"10.1016\/j.ctrv.2020.102106_b0480","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1311194","article-title":"Multitarget stool DNA testing for colorectal-cancer screening","volume":"370","author":"Imperiale","year":"2014","journal-title":"New England J Med"},{"issue":"4","key":"10.1016\/j.ctrv.2020.102106_b0485","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1158\/2159-8290.CD-18-0825","article-title":"Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA","volume":"9","author":"Dudley","year":"2019","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.ctrv.2020.102106_b0490","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41591-020-0933-1","article-title":"Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes","volume":"26","author":"Nuzzo","year":"2020","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ctrv.2020.102106_b0495","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13073-020-00723-8","article-title":"Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors","volume":"12","author":"Smith","year":"2020","journal-title":"Genome Med"},{"key":"10.1016\/j.ctrv.2020.102106_b0500","article-title":"Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy","volume":"7","author":"Springer","year":"2018","journal-title":"Elife"},{"issue":"293","key":"10.1016\/j.ctrv.2020.102106_b0505","doi-asserted-by":"crossref","first-page":"293ra104","DOI":"10.1126\/scitranslmed.aaa8507","article-title":"Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas","volume":"7","author":"Wang","year":"2015","journal-title":"Sci Transl Med"},{"issue":"26","key":"10.1016\/j.ctrv.2020.102106_b0510","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2020.102106_b0515","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","article-title":"Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma","volume":"2","author":"Delfau-Larue","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.ctrv.2020.102106_b0520","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.critrevonc.2019.04.013","article-title":"Cell-free DNA as a biomarker in diffuse large B-cell lymphoma: A systematic review","volume":"139","author":"Arzuaga-Mendez","year":"2019","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"11","key":"10.1016\/j.ctrv.2020.102106_b0525","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1200\/JCO.2009.26.5942","article-title":"Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma","volume":"28","author":"Moskowitz","year":"2010","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"10114","key":"10.1016\/j.ctrv.2020.102106_b0530","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2018","journal-title":"Lancet (London, England)"},{"issue":"17","key":"10.1016\/j.ctrv.2020.102106_b0535","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin\u2019s Lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ctrv.2020.102106_b0540","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin\u2019s Lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2020.102106_b0545","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.critrevonc.2018.05.010","article-title":"Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities","volume":"127","author":"Hiemcke-Jiwa","year":"2018","journal-title":"Crit Rev Oncol\/Hematol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220301444?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737220301444?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:22:32Z","timestamp":1759656152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737220301444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":109,"alternative-id":["S0305737220301444"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102106","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liquid biopsy in lymphoma: Molecular methods and clinical applications","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2020.102106","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102106"}}